Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents

Journal of Medicinal Chemistry

Volumn 48, Issue 11, 2005, Pages 3663-3679

  Newman, Amy Hauck ^a   Grundt, Peter ^a   Nader, Michael A ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 1,2,3,4 TETRAHYDRO 6 (4 METHOXYPHENYLSULFONYLMETHYL)NAPHTHALENE; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; ALCOHOL; BP 897; BUPRENORPHINE; COCAINE; DIAMORPHINE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; HALOPERIDOL; L 741626; L 745829; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NAFADOTRIDE; NALTREXONE; NGB 2904; NICOTINE; PARTIAL AGONIST; QUINPIROLE; S 33084; UNCLASSIFIED DRUG;

ALCOHOLISM; BINDING AFFINITY; CHEMICAL MODIFICATION; COCAINE DEPENDENCE; DRUG ABUSE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; EXTRAPYRAMIDAL SYMPTOM; HEROIN DEPENDENCE; HUMAN; IN VITRO STUDY; NONHUMAN; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOLOGICAL AVAILABILITY; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HUMANS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTANCE-RELATED DISORDERS;

EID: 20144378943     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040190e     Document Type: Review

References (112)

1. Volkow, N. D.; Wang, G. J.; Fowler, J. S.; Logan, J.; Gatley, S. J.; Wong, C.; Hitzemann, R.; Pappas, N. R. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D-2 receptors. J. Pharmacol. Exp. Ther. 1999, 291, 409-415.
2. Volkow, N. D.; Fowler, J. S.; Wang, G. J.; Hitzemann, R.; Logan, J.; Schlyer, D. J.; Dewey, S. L.; Wolf, A. P. Decreased dopamine-D(2) receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993, 14, 169-177.
3. Volkow, N. D.; Fowler, J. S. Addiction, a disease of compulsion and drive: Involvement of the orbitofrontal cortex. Cereb. Cortex 2000, 10, 318-325.
4. Shalev, U.; Grimm, J. W.; Shaham, Y. Neurobiology of relapse to heroin and cocaine seeking: A review. Pharmacol. Rev. 2002, 54, 1-42.
5. Koob, G. F.; Le Moal, M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001, 24, 97-129.
6. Volkow, N. D.; Fowler, J. S.; Wang, G. J.; Swanson, J. M. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol. Psychiatry 2004, 9, 557-569.
7. Leshner, A. I. Addiction is a brain disease, and it matters. Science 1997, 275, 45-47.
8. Kreek, M. J.; LaForge, K. S.; Butelman, E. Pharmacotherapy of addictions. Nat. Rev. Drug Discovery 2002, 1, 710-726.
9. Chao, J.; Nestler, E. J. Molecular neurobiology of drug addiction. Annu. Rev. Med. 2004, 55, 113-132.
10. Cocaine-Fact Sheet; Executive Office of the President, Office of National Drug Control Policy, 2003; www.whitehousedrug-policy.gov.
11. Katz, J. L.; Higgins, S. T. The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology 2003, 168, 21-30.
12. Platt, D. M.; Rowlett, J. K.; Spealman, R. D. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology 2002, 163, 265-282.
13. Mello, N. K.; Negus, S. S. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 1996, 14, 375-424.
14. Howell, L. L.; Wilcox, K. M. The dopamine transporter and cocaine medication development: Drug self-administration in nonhuman primates. J. Pharmacol. Exp. Ther. 2001, 298, 1-6.
15. Spealman, R. D.; Barrett-Larimore, R. L.; Rowlett, J. K.; Platt, D. M.; Khroyan, T. V. Pharmacological and environmental determinants of relapse to cocaine-seeking behavior. Pharmacol. Biochem. Behav. 1999, 64, 327-336.
16. Grabowski, J.; Shearer, J.; Merrill, J.; Negus, S. S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict. Behav. 2004, 29, 1439-1464.
17. Gorelick, D. A.; Gardner, E. L.; Xi, Z. X. Agents in development for the management of cocaine abuse. Drugs 2004, 64, 1547-1573.
18. Childress, A. R.; O'Brien, C. P. Dopamine receptor partial agonists could address the duality of cocaine craving. Trends Pharmacol. Sci. 2000, 21, 6-9.
19. Levant, B. The D-3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol. Rev. 1997, 49, 231-252.
20. 3) as a target for neuroleptics. Nature 1990, 347, 146-151.
21. Sealfon, S. C.; Olanow, C. W. Dopamine receptors: from structure to behavior. Trends Neurosci. 2000, 23, S34-S40.
22. Accili, D.; Fishburn, C. S.; Drago, J.; Steiner, H.; Lachowicz, J. E.; Park, B. H.; Gauda, E. B.; Lee, E. J.; Cool, M. H.; Sibley, D. R.; Gerfen, C. R.; Westphal, H.; Fuchs, S. A targeted mutation of the D-3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 1945-1949.
23. Xu, M.; Koeltzow, T. E.; Santiago, G. T.; Moratalla, R.; Cooper, D. C.; Hu, X. T.; White, N. M.; Graybiel, A. M.; White, F. J.; Tonegawa, S. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 1997, 19, 837-848.
24. Xu, M.; Koeltzow, T. E.; Cooper, D. C.; Tonegawa, S.; White, F. J. Dopamine D3 receptor mutant and wild-type mice exhibit identical responses to putative D3 receptor-selective agonists and antagonists. Synapse 1999, 31, 210-215.
25. Zapata, A.; Witkin, J. M.; Shippenberg, T. S. Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses. Neuropharmacology 2001, 41, 351-359.
26. Caine, S. B.; Negus, S. S.; Mello, N. K.; Patel, S.; Bristow, L.; Kulagowski, J.; Vallone, D.; Saiardi, A.; Borrelli, E. Role of dopamine D2-like receptors in cocaine self-administration: Studies with D2 receptor mutant mice and novel D2 receptor antagonists. J. Neurosci. 2002, 22, 2977-2988.
27. Hackling, A. E.; Stark, H. Dopamine D-3 receptor ligands with antagonist properties. ChemBioChem 2002, 3, 946-961.
28. Luedtke, R. R.; Mach, R. H. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr. Pharm. Des. 2003, 9, 643-671.
29. Wise, R. A. D-1-type and D-2-type contributions to psychomotor sensitization and reward-implications for pharmacological treatment strategies. Clin. Neuropharmacol. 1995, 18, S74-S83.
30. Kosten, T. R.; George, T. P.; Kosten, T. A. The potential of dopamine agonists in drug addiction. Expert Opin. Invest. Drugs 2002, 11, 491-499.
31. Wermuth, C.-G.; Mann, A.; Garrido, F.; Lecomte, J.; Schwartz, J.-C.; Sokoloff, P. Eur. Pat. 0779284, 1997; Chem. Abstr. 1997, 127, 108937.
32. Garcia-Ladona, F. J.; Cox, B. F. BP 897, a selective dopamine D-3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction. CNS Drug Rev. 2003, 9, 141-158.
33. Pilla, M.; Perachon, S.; Sautel, F.; Garrido, F.; Mann, A.; Wermuth, C. G.; Schwartz, J. C.; Everitt, B. J.; Sokoloff, P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D-3 receptor agonist. Nature 1999, 400, 371-375.
34. Aujla, H.; Sokoloff, P.; Beninger, R. J. A dopamine D3 receptor partial agonist blocks the expression of conditioned activity. NeuroReport 2002, 13, 173-176.
35. Le Foll, B.; Frances, H.; Diaz, J.; Schwartz, J. C.; Sokoloff, P. Role of the dopamine D-3 receptor in reactivity to cocaine-associated cues in mice. Eur. J. Neurosci. 2002, 15, 2016-2026.
36. Duarte, C.; Lefebvre, C.; Chaperon, F.; Hamon, M.; Thiebot, M. H. Effects of a dopamine D-3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats. Neuropsychopharmacology 2003, 28, 1903-1915.
37. Campiani, G.; Butini, S.; Trotta, F.; Fattorusso, C.; Catalanotti, B.; Aiello, F.; Gemma, S.; Nacci, V.; Novellino, E.; Stark, J. A.; Cagnotto, A.; Fumagalli, E.; Carnovali, F.; Cervo, L.; Mennini, T. Synthesis and pharmacological evaluation of potent and highly selective D-3 receptor ligands: Inhibition of cocaine-seeking behavior and the role of dopamine D-3/D-2 receptors. J. Med. Chem. 2003, 46, 3822-3839.
38. Cervo, L.; Carnovali, F.; Stark, J. A.; Mennini, T. Cocaine-seeking behavior in response to drug-associated stimuli in rats: Involvement receptors of D-3 and D-2 dopamine receptors. Neuropsychopharmacology 2003, 28, 1150-1159.
39. Beardsley, P. M.; Sokoloff, P.; Balster, R. L.; Schwartz, J. C. The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered. Behav. Pharmacol. 2001, 12, 1-11.
40. Wood, M. D.; Boyfield, I.; Nash, D. J.; Jewitt, F. R.; Avenell, K. Y.; Riley, G. J. Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. Eur. J. Pharmacol. 2000, 407, 47-51.
41. Wicke, K.; Garcia-Ladona, J. The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. Eur. J. Pharmacol. 2001, 424, 85-90.
42. 3 receptor antagonist with high oral bioavailability and CNS penetration in the rat. J. Med. Chem. 2000, 43, 1878-1885.
43. Austin, N. E.; Avenell, K. Y.; Boyfield, I.; Branch, C. L.; Hadley, M. S.; Jeffrey, P.; Johnson, C. N.; Macdonald, G. J.; Nash, D. J.; Riley, G. J.; Smith, A. B.; Stemp, G.; Thewlis, K. M.; Vong, A. K. K.; Wood, M. Novel 2,3,4,5-tetrahydro-1H-3-benzazepines with high affinity and selectivity for the dopamine D-3 receptor. Bioorg. Med. Chem. Lett. 2000, 10, 2553-2555.
44. 3 receptor antagonists. Bioorg. Med. Chem. Lett. 1999, 9, 2059-2064.
45. Millan, M. J.; Gobert, A.; Newman-Tancredi, A.; Lejeune, F.; Cussac, D.; Rivet, J. M.; Audinot, V.; Dubuffet, T.; Lavielle, G. S33084, a novel, potent, selective, and competitive antagonist at dopamine D-3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,-626. J. Pharmacol. Exp. Ther. 2000, 293, 1048-1062.
46. Millan, M. J.; Dekeyne, A.; Rivet, J. M.; Dubuffet, T.; Lavielle, G.; Brocco, M. S33084, a novel, potent, selective, and competitive antagonist at dopamine D-3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 2000, 293, 1063-1073.
47. 3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D-3 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 361, 569-572.
48. Yuan, J.; Chen, X.; Brodbeck, R.; Primus, R.; Braun, J.; Wasley, J. W. F.; Thurkauf, A. NGB 2904 and NGB 2849: Two highly selective dopamine D-3 receptor antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 2715-2718.
49. Personal communication with Dr. Andrew Thurkauf.
50. 3 receptor subtype. J. Med. Chem. 2001, 44, 3175-3186.
51. 3 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 2179-2183.
52. Grundt, P.; Carlson, E. E.; Cao, J. J.; Bennett, J. C.; McElveen, E.; Taylor, M.; Luedtke, R. R.; Newman, A. H. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J. Med. Chem. 2005, 48, 839-848.
53. Dr. Christian Heidbreder, personal communication.
54. Bettinetti, L.; Schlotter, K.; Hubner, H.; Gmeiner, P. Interactive SAR studies: Rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. J. Med. Chem. 2002, 45, 4594-4597.
55. 3 receptor ligands. J. Med. Chem. 2002, 45, 5727-5735.
56. Hackling, A.; Ghosh, R.; Perachon, S.; Mann, A.; Holtje, H. D.; Wermuth, C. G.; Schwartz, J. C.; Sippl, W.; Sokoloff, P.; Stark, H. N-(ω-(4-(2- Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands. J. Med. Chem. 2003, 46, 3883-3899.
57. 3 receptor ligands. ChemBioChem 2004, 5, 508-518.
58. Dutta, A. K.; Fei, X. S.; Reith, M. E. A. A novel series of hybrid compounds derived by combining 2-aminotetralin and piperazine fragments: Binding activity at D-2 and D-3 receptors. Bioorg. Med. Chem. Lett. 2002, 12, 619-622.
59. Dutta, A. K.; Venkataraman, S. K.; Fei, X.-S.; Kolhatkar, R.; Zhang, S.; Reith, M. E. A. Synthesis and biological characterization of novel hybrid 7-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro- naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors. Bioorg. Med. Chem. 2004, 12, 4361-4373.
60. Varady, J.; Wu, X. H.; Fang, X. L.; Min, J.; Hu, Z. J.; Levant, B.; Wang, S. M. Molecular modeling of the three-dimensional structure of dopamine 3 (D-3) subtype receptor: Discovery of novel and potent D-3 ligands through a hybrid pharmacophore- and structure-based database searching approach. J. Med. Chem. 2003, 46, 4377-4392.
61. Reavill, C.; Taylor, S. G.; Wood, M. D.; Ashmeade, T.; Austin, N. E.; Avenell, K. Y.; Boyfield, I.; Branch, C. L.; Cilia, J.; Coldwell, M. C.; Hadley, M. S.; Hunter, A. J.; Jeffrey, P.; Jewitt, F.; Johnson, C. N.; Jones, D. N. C.; Medhurst, A. D.; Middlemiss, D. N.; Nash, D. J.; Riley, G. J.; Routledge, C.; Stemp, G.; Thewlis, K. M.; Trail, B.; Vong, A. K. K.; Hagan, J. J. Pharmacological actions of a novel, high-affinity, and selective human dopamine D-3 receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 2000, 294, 1154-1165.
62. 3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci. 2002, 22, 9595-9603.
63. 3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 2003, 28, 329-338.
64. Austin, N. E.; Baldwin, S. J.; Cutler, L.; Deeks, N.; Kelly, P. J.; Nash, M.; Shardlow, C. E.; Stemp, G.; Thewlis, K.; Ayrton, A.; Jeffrey, P. Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica 2001, 31, 677-686.
65. Macdonald, G. J.; Branch, C. L.; Hadley, M. S.; Johnson, C. N.; Nash, D. J.; Smith, A. B.; Stemp, G.; Thewlis, K. M.; Vong, A. K. K.; Austin, N. E.; Jeffrey, P.; Winborn, K. Y.; Boyfield, I.; Hagan, J. J.; Middlemiss, D. N.; Reavill, C.; Riley, G. J.; Watson, J. M.; Wood, M.; Parker, S. G.; Ashby, C. R. Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl)) phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3- benzazepine (SB-414796): A potent and selective dopamine D-3 receptor antagonist. J. Med. Chem. 2003, 46, 4952-4964.
66. Schwartz, J. C.; Levesque, D.; Martres, M. P.; Sokoloff, P. Dopamine-D(3) receptoi-basic and clinical aspects. Clin. Neuropharmacol. 1993, 16, 295-314.
67. Di Chiara, G.; Imperato, A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 5274-5278.
68. Koob, G. F. Neural mechanisms of drug reinforcement. Ann. N.Y. Acad. Sci. 1992, 654, 171-191.
69. Le Foll, B.; Schwartz, J. C.; Sokoloff, P. Dopamine D-3 receptor agents as potential new medications for drug addiction. Eur. Psychiatry 2000, 15, 140-146.
70. Sokoloff, P.; Martres, M. P.; Giros, B.; Bouthenet, M. L.; Schwartz, J. C. The 3rd dopamine receptor (D3) as a novel target for antipsychotics. Biochem. Pharmacol. 1992, 43, 659-666.
71. Shafer, R. A.; Levant, B. The D-3 dopamine receptor in cellular and organismal function. Psychopharmacology 1998, 135, 1-16.
72. Joyce, J. N. Dopamine D-3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 2001, 90, 231-259.
73. Richtand, N. M.; Goldsmith, R. J.; Nolan, J. E.; Berger, S. P. The D3 dopamine receptor and substance dependence. J. Addict. Dis. 2001, 20, 19-32.
74. Richtand, N. M.; Woods, S. C.; Berger, S. P.; Strakowski, S. M. D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci. Biobehav. Rev. 2001, 25, 427-443.
75. Sautel, F.; Griffon, N.; Sokoloff, P.; Schwartz, J. C.; Launay, C.; Simon, P.; Costentin, J.; Schoenfelder, A.; Garrido, F.; Mann, A.; Wermuth, C. G. Nafadotride, a potent preferential dopamine D-3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 1995, 275, 1239-1246.
76. Richtand, N. M.; Logue, A. D.; Welge, J. A.; Perdiue, J.; Tubbs, L. J.; Spitzer, R. H.; Sethuraman, G.; Geracioti, T. D. The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine. Brain Res. 2000, 867, 239-242.
77. Caine, S. B.; Koob, G. F. Modulation of cocaine self-administration in the rat through D-3 dopamine-receptors. Science 1993, 260, 1814-1816.
78. Sinnott, R. S.; Mach, R. H.; Nader, M. A. Dopamine D-2/D-3 receptors modulate cocaine's reinforcing and discriminative stimulus effects in rhesus monkeys. Drug Alcohol Depend. 1999, 54, 97-110.
79. Staley, J. K.; Mash, D. C. Adaptive increase in D-3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J. Neurosci. 1996, 16, 6100-6106.
80. Segal, D. M.; Moraes, C. T.; Mash, D. C. Up-regulation of D-3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Mol. Brain Res. 1997, 45, 335-339.
81. 3H]spiperone binding. Naunyn-Schmiedeberg's Arch. Pharmacol. 1998, 358, 342-350.
82. Neisewander, J. L.; Fuchs, R. A.; Tran-Nguyen, L. T. L.; Weber, S. M.; Coffey, G. P.; Joyce, J. N. Increases in dopamine D-3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: Implications for cocaine-seeking behavior. Neuropsychopharmacology 2004, 29, 1479-1487.
83. Millan, M. J.; Di Cara, B.; Hill, M.; Jackson, M.; Joyce, J. N.; Brotchie, J.; McGuire, S.; Crossman, A.; Smith, L.; Jenner, P.; Gobert, A.; Peglion, J. L.; Brocco, M. S32504, a novel naphtoxazine agonist at dopamine D-3/D-2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison with ropinirole. J. Pharmacol. Exp. Ther. 2004, 309, 921-935.
84. Chausmer, A. L.; Katz, J. L. The role of D2-like dopamine receptors in the locomotor stimulant effects of cocaine in mice. Psychopharmacology 2001, 155, 69-77.
85. Piazza, P. V.; Deminiere, J. M.; Lemoal, M.; Simon, H. Factors that predict individual vulnerability to amphetamine self-administration. Science 1989, 245, 1511-1513.
86. Stephens, D. N.; Mead, A. N. Behavioural plasticity-induced changes in drug response. Commentary on Badiani and Robinson drug-induced neurobehavioral plasticity: the role of environmental context. Behav. Pharmacology 2004, 15, 377-380.
87. Volkow, N. D.; Wang, G. J.; Fowler, J. S.; Logan, J.; Gatley, S. J.; Gifford, A.; Hitzemann, R.; Ding, Y. S.; Pappas, N. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D-2 receptor levels. Am. J. Psychiatry 1999, 156, 1440-1443.
88. Morgan, D.; Grant, K. A.; Gage, H. D.; Mach, R. H.; Kaplan, J. R.; Prioleau, O.; Nader, S. H.; Buchheimer, N.; Ehrenkaufer, R. L.; Nader, M. A. Social dominance in monkeys: dopamine D-2 receptors and cocaine self-administration. Nat. Neurosci. 2002, 5, 169-174.
89. Stanwood, G. D.; Lucki, I.; McGonigle, P. Differential regulation of dopamine D2 and D3 receptors by chronic drug treatments. J. Pharmacol. Exp. Ther. 2000, 295, 1232-1240.
90. Nader, M. A.; Mach, R. H. Self-administration of the dopamine D-3 agonist 7-OH-DPAT in rhesus monkeys is modified by prior cocaine exposure. Psychopharmacology 1996, 125, 13-22.
91. Pulvirenti, L.; Koob, G. F. Being partial to psychostimulant addiction therapy. Trends Pharmacol. Sci. 2002, 23, 151-153.
92. Gal, K.; Gyertyan, I. Targeting the dopamine D-3 receptor cannot influence continuous reinforcement cocaine self-administration in rats. Brain Res. Bull. 2003, 61, 595-601.
93. Xi, Z.; Gilbert, J.; Campos, A.; Ashby, C. R., Jr.; Gardner, E. L.; Newman, A. H. The dopamine D3 receptor antagonist NGB 2904 inhibits cocaine reward and cocaine-triggered reinstatement of cocaine-seeking behavior. Presented at the 34th Annual Meeting of the Society for Neuroscience, New Orleans, LA, 2003.
94. Ashby, C. R.; Paul, M.; Gardner, E. L.; Heidbreder, C. A.; Hagan, J. J. Acute administration of the selective D-3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 2003, 48, 154-156.
95. Di Chiara, G.; North, R. A. Neurobiology of opiate abuse. Trends Pharmacol. Sci. 1992, 13, 185-193.
96. Koob, G. F.; Bloom, F. E. Cellular and molecular mechanisms of drug-dependence. Science 1988, 242, 715-723.
97. Hennigfield, J. E.; Fant, R. V.; Gitchell, J.; Shiffman, S. Tobacco dependence-Global public health potential for new medications development and indications. Ann. N.Y. Acad. Sci. 2000, 909, 247-256.
98. Goldberg, S. R.; Morse, W. H.; Goldberg, D. M. Behavior maintained under a 2nd order schedule by intramuscular injection of morphine or cocaine in rhesus-monkeys. J. Pharmacol. Exp. Ther. 1976, 199, 278-286.
99. Le Foll, B.; Diaz, J.; Sokoloff, P. Increased dopamine D-3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 2003, 47, 176-183.
100. Andreoli, M.; Tessari, M.; Pilla, M.; Valerio, E.; Hagan, J. J.; Heidbreder, C. A. Selective antagonism at dopamine D-3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 2003, 28, 1272-1280.
101. Corrigall, W. A.; Coen, K. M. Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology 1991, 104, 171-176.
102. McEvoy, J. P.; Freudenreich, O.; Levin, E. D.; Rose, J. E. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 1995, 119, 124-126.
103. Caskey, N. H.; Jarvik, M. E.; Wirshing, W. C. The effects of dopaminergic D-2 stimulation and blockade on smoking behavior. Exp. Clin. Psychopharmacol. 1999, 7, 72-78.
104. Murphy, M. F. G.; Hey, K.; Johnstone, E.; Munafo, M.; Walton, R.; Willis, B.; Harrison, P. J. Bromocriptine use is associated with decreased smoking rates. Addict. Biol. 2002, 7, 325-328.
105. Heidbreder, C. A.; Andreoli, M.; Marcon, C.; Thanos, P. K.; Ashby, C. R.; Gardner, E. L. Role of dopamine D-3 receptors in the addictive properties of ethanol. Drugs Today 2004, 40, 355-365.
106. Silvestre, J. S.; O'Neill, M. F.; Fernandez, A. G.; Palacios, J. M. Effects of a range of dopamine receptor agonists and antagonists on ethanol intake in the rat. Eur. J. Pharmacol. 1996, 318, 257-265.
107. Boyce, J. M.; Risinger, F. O. Enhancement of ethanol reward by dopamine D3 receptor blockade. Brain Res. 2000, 880, 202-206.
108. Narita, M.; Soma, M.; Tamaki, H.; Narita, M.; Suzuki, T. Intensification of the development of ethanol dependence in mice lacking dopamine D-3 receptor. Neurosci. Lett. 2002, 324, 129-132.
109. Hocke, C.; Prante, O.; Löber, S.; Hübner, H.; Gmeiner, P.; Kuwert, T. Synthesis and radioiodination of selective ligands for the dopamine D3 receptor subtype. Bioorg. Med. Chem. Lett. 2004, 14, 3963-3966.
110. Sovago, J.; Farde, L.; Halldin, C.; Langer, O.; Laszlovszky, I.; Kiss, B.; Gulyas, B. Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, C-11 RGH-1756 in the monkey brain. Neurochem. Int. 2004, 45, 609-617.
111. Wong, D. F.; Gjedde, A. Dopamine D3 receptor density and occupancy determined with selective D3 inhibitor and C-11 raclopride (D2/D3) PET. J. Nucl. Med. 2003, 44, 256P-256P.
112. Pilla, M.; Hutcheson, D. M.; Adib-Samil, P.; Everitt, B. J. Seeking responses for cocaine, heroine and natural reinforcers are differentially modulated by dopamine D3 receptors. Presented at the 31st Annual Meeting of the Society for Neuroscience, San Diego, CA, 2001.